DelveInsight’s ‘Thyroid Cancer Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline Thyroid Cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Thyroid Cancer pipeline domain.
For Thyroid Cancer emerging drugs, the Thyroid Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Thyroid Cancer Pipeline Report
- Over 40+ Thyroid Cancer pipeline therapies are in various stages of development, and their anticipated acceptance in the Thyroid Cancer market would significantly increase market revenue.
- Leading Thyroid Cancer companies developing novel drug candidates to improve the Thyroid Cancer treatment landscape include Shanghai Henlius Biotech, AffyImmune Therapeutics, Inc., Taizhou Hanzhong biomedical co. LTD, Bristol-Myers Squibb, Takeda Oncology, Merck Sharp & Dohme Corp., Genentech, Inc., VBL Therapeutics, Eli Lilly and Company, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Purple Biotech, Boston Pharmaceuticals, Xynomic Pharmaceuticals, Inc., Turning Point Therapeutics, Inc., Iovance Biotherapeutics, Inc., Hoffmann-La Roche, Hutchison Medipharma Limited, Theratechnologies, TransThera Sciences (Nanjing), Inc., Novartis Oncology, SOTIO Biotech AG, Ono Pharmaceutical, Debiopharm, Tmunity Therapeutics, Codiak BioSciences, Oncoceutics, GlobeImmune, C4 Therapeutics, Innovative Cellular Therapeutics, Applied Pharmaceutical, and others.
- Promising Thyroid Cancer pipeline therapies in various stages of development include HLX208, AIC100, HX008, Nivolumab, Ipilimumab, MLN0128, Pembrolizumab, Vemurafenib, VB-111, LOXO-260, Anlotinib hydrochloride, HA121-28, CM-24, BOS172738, XP-102, TPX-0046, LN 145, Alectinib, Surufatinib, TH1902, TT-00420, Spartalizumab, SO-C101, LY3410738, Binimetinib, DEBIO 1124, CDK-002, ONC201, GI 6207, APS03118, exoASO STAT6, and others.
- In October 2022, Eisai announced the final results of a real-world data (RWD) study evaluating the clinical efficacy of LENVIMA® (lenvatinib) as a first-line therapy for patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC).
- In September 2022, the Oncomine Dx Target Test was approved by the FDA as a companion diagnostic to aid in the identification of RET fusions in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), advanced/metastatic thyroid cancer, or advanced/metastatic medullary thyroid cancer (MTC) who may be candidates for selpercatinib (Retevmo).
Request a sample and discover the recent breakthroughs happening in Thyroid Cancer pipeline landscape @Thyroid Cancer Pipeline Report
Thyroid Cancer Overview
Thyroid cancer develops in the thyroid cells at the base of the neck, directly behind Adam’s apple. Hormones secreted by the thyroid gland regulate heart rate, blood pressure, body temperature, and weight. Thyroid cancer symptoms may not appear right away. However, neck pain and swelling are common symptoms of Thyroid Cancer. The causes of Thyroid Cancer are still unknown. Thyroid cancer comes in many forms, including Papillary Thyroid Cancer, Medullary Thyroid Cancer, Anaplastic Thyroid Cancer, and others. Some grow slowly, while others may grow quickly.
Thyroid cancer is commonly diagnosed using physical exams, blood tests, imaging tests, and genetic testing. Thyroid cancer treatment options include surgery, radioactive iodine therapy (Radioiodine), and thyroid hormone therapy.
Survival rates for thyroid cancer are rising. Some doctors believe this is because new technology allows them to detect previously undetected thyroid tumors. Thyroid cancer screening tests are also being researched in clinical trials.
Find out more about the diagnosis and treatment of patients with Thyroid Cancer @Thyroid Cancer Treatment
Thyroid Cancer Pipeline Analysis: Drug Profile
Donafenib: Suzhou Zelgen Biopharmaceuticals
Suzhou Zelgen Biopharmaceuticals is developing donafenib, an orally administered multikinase inhibitor, for the treatment of advanced cancers. With potential antineoplastic activity, the product targets Raf kinase and other receptor tyrosine kinases (RTKs). It is currently in phase III of development for the treatment of thyroid cancer.
Anlotinib: Jiangsu Chia-Tai Tianqing Pharmaceutical
Anlotinib is a tyrosine kinase inhibitor that is taken orally and targets the vascular endothelial growth factor receptor (VEGFR), the fibroblast growth factor receptor (FGFR), the platelet-derived growth factor receptors (PDGFR), and c-kit. It is currently in phase III of development for the treatment of thyroid cancer.
Thyroid Cancer Pipeline Therapies and Key Companies
- Donafenib: Suzhou Zelgen Biopharmaceuticals
- Anlotinib: Jiangsu Chia-Tai Tianqing Pharmaceutical
- Nivolumab: Bristol-Myers Squibb
- RX208: Suzhou NeuPharma
- AIC100: AffyImmune Therapeutics
- HA121-28: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- CM-24: Purple Biotech
Learn more about the Thyroid Cancer emerging pipeline therapies @Thyroid Cancer Clinical Trials
Thyroid Cancer Pipeline Therapeutics Assessment
- By Product Type
-
- Monotherapy
- Combination Therapy
- By Stage
-
- Discovery
- Pre-Clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
-
- Oral
- Parenteral
- Subcutaneous
- Topical
- Intravenous
- By Molecule Type
- Gene therapy
- Small molecule
- Polymers
- Peptides
- Monoclonal antibodies
Scope of the Thyroid Cancer Pipeline Report
- Coverage: Global
- Key Thyroid Cancer Companies: Shanghai Henlius Biotech, AffyImmune Therapeutics, Inc., Taizhou Hanzhong biomedical co. LTD, Bristol-Myers Squibb, Takeda Oncology, Merck Sharp & Dohme Corp., Genentech, Inc., VBL Therapeutics, Eli Lilly and Company, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Purple Biotech, Boston Pharmaceuticals, Xynomic Pharmaceuticals, Inc., Turning Point Therapeutics, Inc., Iovance Biotherapeutics, Inc., Hoffmann-La Roche, Hutchison Medipharma Limited, Theratechnologies, TransThera Sciences (Nanjing), Inc., Novartis Oncology, SOTIO Biotech AG, Ono Pharmaceutical, Debiopharm, Tmunity Therapeutics, Codiak BioSciences, Oncoceutics, GlobeImmune, C4 Therapeutics, Innovative Cellular Therapeutics, Applied Pharmaceutical, and others.
- Key Thyroid Cancer Pipeline Therapies: HLX208, AIC100, HX008, Nivolumab, Ipilimumab, MLN0128, Pembrolizumab, Vemurafenib, VB-111, LOXO-260, Anlotinib hydrochloride, HA121-28, CM-24, BOS172738, XP-102, TPX-0046, LN 145, Alectinib, Surufatinib, TH1902, TT-00420, Spartalizumab, SO-C101, LY3410738, Binimetinib, DEBIO 1124, CDK-002, ONC201, GI 6207, APS03118, exoASO STAT6, and others.
Dive deep into rich insights for Thyroid Cancer emerging therapies and assessment; visit @Thyroid Cancer Emerging Therapies
Table of Contents
| 1. | Introduction |
| 2. | Executive Summary |
| 3. | Overview |
| 4. | Pipeline Therapeutics |
| 5. | Late Stage Products (Phase III) |
| 6. | Mid Stage Products (Phase II) |
| 7. | Early Stage Products (Phase I/II) |
| 8. | Preclinical Stage Products |
| 9. | Discovery Stage Products |
| 10. | Therapeutic Assessment |
| 11. | Inactive Products |
| 12. | Collaborations Assessment- Licensing / Partnering / Funding |
| 13. | Unmet Needs |
| 14. | Market Drivers and Barriers |
| 15. | Appendix |
| 16. | About DelveInsight |
For further information on the Thyroid Cancer pipeline therapeutics, reach out @Targetted Drug Therapy Thyroid Cancer
Related Reports
Thyroid Cancer Epidemiology Forecast
Thyroid Cancer Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Thyroid Cancer epidemiology in the 7MM.
Thyroid Cancer Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Thyroid Cancer companies such as Bristol-Myers Squibb, Genentech, AffyImmune Therapeutics, Inc., Taizhou Hanzhong biomedical co. LTD, among others.
Thyroid Hormone Receptor Agonists Pipeline
Thyroid Hormone Receptor Agonists Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Thyroid Hormone Receptor Agonists companies such as Terns Pharmaceuticals, Ascletis, Autobahn Therapeutics, among others.
Papillary Thyroid Cancer Pipeline
Papillary Thyroid Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Papillary Thyroid Cancer companies such as the University of Colorado, Assiut University, University Health Network, among others.
Medullary Thyroid Cancer Pipeline
Medullary Thyroid Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Medullary Thyroid Cancer companies such as the Eli Lilly, Exelixis, Columbia University, among others.
Anaplastic Thyroid Cancer Pipeline
Anaplastic Thyroid Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Anaplastic Thyroid Cancer companies such as the Novartis, AstraZeneca, Fujian Medical University, among others.
Other Trending Reports
Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market |Spirometers Market | Hemodynamic Monitoring Systems Market | Deep Brain Stimulation Devices Market | Genital Herpes Market | Guillain-Barre Syndrome (GBS) Market | Hot Flashes Market | Human Immunodeficiency Virus Type-1 (HIV-1) Market | Hypertrophic Scar Market | Sinus Dilation Devices Market | Artificial Cornea and Corneal Implant Market |Peripheral Neuritis Market | Peripheral Vascular Devices Market | Diphtheria Market | Glioma Market | Fallopian Tube Cancer Market | Implantable Cardioverter Defibrillators (ICDs) Market | Smart Inhalers Market | Thyroid Cancer Market | Hemostasis Market | Peptic Ulcers Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187